Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies—EORTC 18991
Marna G. Bouwhuis(Erasmus MC), Alexander M.M. Eggermont(University Medical Center Utrecht), Cornelis J.A. Punt(Utrecht University), Poulam M. Patel(Nottingham University Hospitals NHS Trust), Stefan Suciu(St James's University Hospital), Timo L.M. ten Hagen(Erasmus MC), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), François Salès(Institut Jules Bordet), Alan Spatz(Jewish General Hospital), Wim H.J. Kruit(Erasmus MC), Alessandro Testori(European Organisation for Research and Treatment of Cancer)
Cited by 84
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k